The DOI matches its Crossref record.
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bergqvist, C., & Ezzedine, K. (2020) · Dermatology · doi:10.1159/000506103 · Cited by 799
Vitiligo: Mechanisms of Pathogenesis and Treatment
Frisoli, M. L., Essien, K., & Harris, J. E. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100919-023531 · Cited by 618
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
Rosmarin, D., Passeron, T., Pandya, A. G., Grimes, P., Harris, J. E., Desai, S. R., Lebwohl, M., Ruer-Mulard, M., Seneschal, J., Wolkerstorfer, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118828 · Cited by 316
Self-citationEmerging Topical and Systemic JAK Inhibitors in Dermatology
Solimani, F., Meier, K., & Ghoreschi, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02847 · Cited by 308
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
Fragoulis, G. E., McInnes, I. B., & Siebert, S. (2019) · Rheumatology · doi:10.1093/rheumatology/key276 · Cited by 296
Vitiligo: A focus on pathogenesis and its therapeutic implications
Bergqvist, C., & Ezzedine, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15743 · Cited by 277
Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy
Boniface, K., Seneschal, J., Picardo, M., & Taïeb, A. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8622-7 · Cited by 272
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
Rosmarin, D., Pandya, A. G., Lebwohl, M., Grimes, P., Hamzavi, I., Gottlieb, A. B., Butler, K., Kuo, F., Sun, K., Ji, T., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30609-7 · Cited by 271
Self-citationT cells and the skin: from protective immunity to inflammatory skin disorders
Ho, A. W., & Kupper, T. S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0162-3 · Cited by 241
Skin Pigmentation Types, Causes and Treatment—A Review
Thawabteh, A. M., Jibreen, A., Karaman, D., Thawabteh, A., & Karaman, R. (2023) · Molecules · doi:10.3390/molecules28124839 · Cited by 233
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
Qi, F., Liu, F., & Gao, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790125 · Cited by 203
Unmet medical needs in chronic, non-communicable inflammatory skin diseases
Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.875492 · Cited by 158
Predictors of Response to Topical Ruxolitinib in Non‐segmental Vitiligo: A Narrative Review
Bettolini, L., Maione, V., Carugno, A., Fratton, Z., Errichetti, E., Crivellari, M., Cartocci, A., Maronese, C. A., Venturini, M., Zerbinati, N., et al. (2026) · Australasian Journal of Dermatology · doi:10.1111/ajd.70090 · Cited by 3
Metadata
- Authors
- Rothstein, B., Joshipura, D., Saraiya, A., Abdat, R., Ashkar, H., Turkowski, Y., Sheth, V., Huang, V., Au, S. C., Kachuk, C., Dumont, N., Gottlieb, A. B., & Rosmarin, D.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 76
- Issue
- 6
- Pages
- 1054-1060.e1
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2604581907
- Cited by
- 189
- References
- 0
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.